New thiophene, thienopyridine and thiazoline-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents and multitargeting kinase inhibitors

Bioorg Chem. 2022 Oct:127:105964. doi: 10.1016/j.bioorg.2022.105964. Epub 2022 Jun 14.

Abstract

Multitargeting kinase inhibitors recently proved to be a profitable approach for conquering cancer proliferation. The current study represents the design and synthesis of new thiophene, thienopyridine, and thiazoline-based derivatives 4-14a,b. All the target compounds were examined in vitro against three cancer cell lines; the liver (HepG-2), breast (MCF-7), and colon (HCT-116) where the thiophene-based compounds 5a-c, demonstrated the most potent activity. Furthermore, the latter derivatives revealed a safety profile against WI-38 normal cell line of selectivity indices ranging from 4.43 to 17.44. In vitro enzyme assay of 5a-c revealed that the carbohydrazide analog 5c has the most promising multitargeting inhibiting activity against Pim-1, VEGFR-2, and EGFRWT enzymes of IC50 values; 0.037 ± 0.02, 0.95 ± 0.24, and 0.16 ± 0.05 µM, respectively. As it was the most potent analog, 5c was further subjected to cell cycle and apoptosis analysis. The results indicated that it induced preG1 arrest and an apoptotic effect in the early and late stages. Moreover, further apoptosis studies were carried out for 5c to evaluate its proapoptotic potential. Interestingly, 5c enhanced the levels of Bax/Bcl-2 ratio, p53, and active caspase 3 by 18, 6.4, and 24 folds, respectively compared to the untreated cells. The antimicrobial evaluation showed that only compounds 3 and 5a produced broad-spectrum potency, while 5b and 5c exhibited outstanding antifungal effects. Finally, a molecular docking study was carried out to discover the probable interactions of compound 5c with the active sites of Pim-1, VEGFR-2, and EGFRWT kinases.

Keywords: Antiproliferative activity; Apoptosis; Cell cycle; EGFR; Pim-1; Proapoptotic potential; Thiazoline; Thienopyridine; Thiophene; VEGFR-2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Screening Assays, Antitumor
  • ErbB Receptors / metabolism
  • Molecular Docking Simulation
  • Molecular Structure
  • Protein Kinase Inhibitors
  • Structure-Activity Relationship
  • Thienopyridines / pharmacology
  • Thiophenes / chemistry
  • Vascular Endothelial Growth Factor Receptor-2*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Thienopyridines
  • Thiophenes
  • ErbB Receptors
  • Vascular Endothelial Growth Factor Receptor-2